← Back to patent-cliff list
Levamlodipine Besylate/Valsartan (Sunshine Novo)
Tier C — Watch / tradeLevamlodipine Besylate/Valsartan (Sunshine Novo)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AT1, VDCCs
Indications (approved)：Hypertension, Essential hypertension
Regional status
US
-
EU
-
China
Phase III
2023-03-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Levamlodipine Besylate/Valsartan (Sunshine Novo)?
Approved indications include: Hypertension, Essential hypertension.
When does the Levamlodipine Besylate/Valsartan (Sunshine Novo) patent expire?
No public expiry year is available for Levamlodipine Besylate/Valsartan (Sunshine Novo) yet; this page updates once verified.
How do I get a quote for Levamlodipine Besylate/Valsartan (Sunshine Novo) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03